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Open accAbstract Background: High hospital volume is associated with better outcomes after oeso-
phagectomy and gastrectomy. In the Netherlands, a minimal volume standard of 10 oeso-
phagectomies per year was introduced in 2006. For gastrectomy, no minimal volume
standard was set. Aims of this study were to describe changes in hospital volumes, mortality
and survival and to explore if high hospital volume is associated with better outcomes after
oesophagectomy and gastrectomy in the Netherlands.
Methods: From 1989 to 2009, 24,246 patients underwent oesophagectomy (N = 10,025) or
gastrectomy (N = 14,221) in the Netherlands. Annual hospital volumes were deﬁned as very
low (1–5), low (6–10), medium (11–20), and high (P21). Volume–outcome analyses were per-
formed using Cox regression, adjusting for year of diagnosis, case-mix and the use of multi-
modality treatment.
Results: From 1989 to 2009, the percentage of patients treated in high-volume hospitals
increased for oesophagectomy (from 7% to 64%), but decreased for gastrectomy (from 8%
to 5%). Six-month mortality (from 15% to 7%) and 3-year survival (from 41% to 52%)
improved after oesophagectomy, and to a lesser extent after gastrectomy (6-month mortality:64
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J.L. Dikken et al. / European Journal of Cancer 48 (2012) 1004–1013 100515%-10%, three-year survival: 55–58%). High hospital volume was associated with lower 6-
month mortality (hazard ratio (HR) 0.48, P < 0.001) and longer 3-year survival (HR 0.77,
P < 0.001) after oesophagectomy, but not after gastrectomy.
Conclusions: Oesophagectomy was effectively centralised in the Netherlands, improving mor-
tality and survival. Gastrectomies were mainly performed in low volumes, and outcomes after
gastrectomy improved to a lesser extent, indicating an urgent need for improvement in quality
of surgery and perioperative care for gastric cancer in the Netherlands.
 2012 Elsevier Ltd. Open access under the Elsevier OA license. 1. Introduction
Oesophageal and gastric cancers are highly lethal
malignancies.1 Despite surgery, which is the cornerstone
of curative treatment for these diseases, survival is low,
and compared to other surgical procedures, postopera-
tive mortality is high. In the Western world, 5-year sur-
vival rates are below 25% for oesophageal cancer,2,3 and
do not exceed 40% for gastric cancer.2,4 Reported post-
operative mortality after oesophagectomy varies from
2% for specialised centres5 to 10% for certain nationwide
registries.6 After gastrectomy, postoperative mortality
varies between 3% to well above 10%.7,8 To reduce mor-
tality and improve survival, it has been suggested that
these high-risk operations should be performed in spec-
ialised centres with adequate annual volumes. Many
studies have investigated volume–outcome relations
after oesophagectomy and gastrectomy, but the relative
importance of volume after gastrectomy in particular is
disputed.9,10
In the Netherlands, a relation between high hospital
volume and low postoperative mortality was demon-
strated for oesophagectomy in 2000.11 Despite extensive
discussions within the Dutch Society of Surgery, this
study did not lead to signiﬁcant changes in referral pat-
terns for oesophagectomies on anational level. Therefore,
as of 2006 aminimumvolume of 10 oesophagectomies per
year was enforced by the Dutch Healthcare Inspectorate,
and as of 2011 the Dutch Society of Surgery recommends
a minimal volume of 20 oesophagectomies per year. For
gastrectomy, no minimum volume standard has been
established in the Netherlands.
Aims of the present study were to describe changes in
annual hospital volumes, postoperative mortality, sur-
vival and lymph node yields for oesophagectomy and
gastrectomy in the Netherlands between 1989 and
2009, and to explore whether there is any association
between annual hospital volume for oesophagectomy
and gastrectomy and postoperative mortality, survival
and lymph node yield.
2. Patients and methods
2.1. The Netherlands Cancer Registry
Data were obtained from the Netherlands Cancer
Registry (NCR), which covers all hospitals in theNetherlands, a country of 16.5 million inhabitants.
Information on all newly diagnosed malignancies is rou-
tinely collected by trained registrars from the hospital
records 6–18 months after diagnosis. Quality and com-
pleteness of the data are high.12
Topography andmorphologywere coded according to
the International Classiﬁcation of Diseases for Oncology
(ICD-O).13 ICD-O morphology codes were used to clas-
sify tumours as adenocarcinoma (8140-8145, 8190,
8201-8211, 8243, 8255-8401, 8453-8520, 8572, 8573,
8576), squamous cell carcinoma (SCC) (8032, 8033,
8051-8074, 8076-8123) and other or unknown histology
(8000-8022, 8041-8046, 8075, 8147, 8153, 8200, 8230-
8242, 8244-8249, 8430, 8530, 8560, 8570, 8574, 8575).
Tumours were staged according to the International
UnionAgainstCancer (UICC)TumourNodeMetastases
(TNM) classiﬁcation in use in the year of diagnosis. Vital
status was initially obtained from municipal registries,
and from 1994 onwards from the nationwide population
registries network. These registries provide complete cov-
erage of all deceased Dutch citizens. Follow-up was com-
plete for all patients until 31st December 2009. The study
was approved by the NCR Review Board.
2.2. Patients
Between January 1989 and December 2009, 71,090
patients with oesophageal or gastric cancer were diag-
nosed in the Netherlands (Fig. 1). Patients who did
not undergo surgical treatment (N = 43,646) and
patients without information on the hospital where the
diagnosis was established, or where surgery was per-
formed (N = 8), were excluded, leaving 27,436 resections
available to calculate annual hospital volumes. After
establishing annual hospital volumes, patients with in-
situ carcinoma (N = 288), and patients with distant
metastases (N = 2902) were excluded, leaving 24,246
patients with non-metastatic invasive carcinoma avail-
able for volume–outcome analyses.
2.3. Surgery
Since the NCR is a topography-based registry, and
the type of surgery was not speciﬁed for every patient,
the distinction between oesophageal and gastric cancer
surgery was based on tumour location. Oesophagecto-
mies were deﬁned as resections for cancers of the
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Fig. 1. Study proﬁle.
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whereas gastrectomies were deﬁned as resections for
non-cardia gastric cancer (C16.1-16.9). To ensure this
distinction did not inﬂuence the results, volume–out-
come analyses were repeated with cardia cancer coded
as gastric cancer. Yearly resection rates were calculated
as the number of resections relative to the number of
cancers diagnosed in a year.
2.4. Hospital volumes
Annual hospital volumes were deﬁned as the number
of oesophagectomies or gastrectomies per hospital per
year. Clinically relevant volume categories were deﬁned
as very low (1–5/year), low (6–10/year), medium (11–20/
year), and high (P21/year). From 2005 to 2009, the hos-
pital where the surgery was performed was registered for
all patients. Before 2005, the hospital where the surgery
was performed was only registered in 53% of the cases,
and showed an 80% overlap with the hospital of diagno-
sis. For the remaining 47%, with an unknown surgical
hospital, the hospital of diagnosis was used to calculate
hospital volume.
2.5. Statistical analysis
Oesophagectomy and gastrectomy were analysed sep-
arately. Resection rates and hospital volumes over time
were analysed with the Chi-square test. Changes in 6-
month mortality and 3-year survival were analysed with
stratiﬁed Cox regression, adjusted for sex, age, socio-
economic status,14 stage, morphology, preoperative
therapy use and postoperative therapy use (only for 3-
year survival). Overall survival (OS) was calculated from
the day of diagnosis until death, because the date of sur-
gery was not available before 2005. Six-month OS was
calculated unconditionally, while 3-year OS was calcu-
lated conditionally on surviving the ﬁrst 6 months afterdiagnosis. Lymph node yields over time were adjusted
for sex, age, stage and morphology.
For volume–outcome analyses, the patient was con-
sidered the unit of analysis, with hospital volume as
the exposure factor. Diﬀerences in survival estimates
were calculated with Cox regression, stratiﬁed for hospi-
tal volume and adjusted for the factors used to analyse
changes over time and for clustering of deaths within
hospitals.15 Diﬀerences in lymph node yields were ana-
lysed with generalised estimated equations, adjusted
for the factors used to analyse changes over time and
for clustering within hospitals.
Besides analysing hospital volume in categories,
annual volume was analysed as a linear variable. Anal-
yses were performed with SPSS (version 17.0.2) and R
(version 2.12.2).
3. Results
3.1. Patient characteristics
Between 1989 and 2009, 24,246 patients with resect-
able, non-metastatic oesophageal (N = 10,025) or gas-
tric cancer (N = 14,221) underwent a resection in the
Netherlands. Patient characteristics (Tables 1 and 2)
varied between the diﬀerent volume categories. For
oesophageal cancer, high-volume hospitals treated more
patients with squamous cell carcinoma and more
advanced tumour stages. For gastric cancer, patients
treated in high-volume hospitals were older and had
more advanced tumours.
3.2. Hospital volumes over time
From 1989 to 2009, the annual number of oesophag-
ectomies doubled (from 352 to 723), and the annual
number of gastrectomies steadily decreased (from 1107
to 495) (Fig. 2).
Table 1
Patient characteristics for all surgically treated patients with non-metastatic invasive oesophageal cancer in the Netherlands between 1989 and 2009
(N = 10,025).
VLV (1–5) LV (6–10) MV (11–20) HV (P21) P
N % N % N % N %
Total 2914 100 2695 100 1494 100 2922 100
Sex
Male 2213 76 2058 76 1130 76 2249 77 0.73
Female 701 24 637 24 364 24 673 23
Age category
<60 936 32 956 35 515 34 1032 35 0.002
60–75 1630 56 1456 54 814 54 1632 56
>75 348 12 283 11 165 11 258 9
SES
Low 274 9 308 11 165 11 259 9 <0.001
Medium 2415 83 2124 79 1208 81 2131 73
High 135 5 123 5 53 4 115 4
Unknown 90 3 140 5 68 5 417 14
Morphology
Adenocarcinoma 2288 79 2006 74 1113 74 2134 73 <0.001
SCC 554 19 628 23 341 23 732 25
Other 72 2 61 2 40 3 56 2
TNM stage
I 622 21 512 19 285 19 522 18 <0.001
II 1161 40 1093 41 576 39 1068 37
III 988 34 940 35 535 36 1112 38
IVa 30 1 30 1 23 2 25 1
Unknown 113 4 120 4 75 5 195 7
Preoperative therapy
Yes 165 6 244 9 357 24 938 32 <0.001
No 2749 94 2451 91 1137 76 1984 68
Postoperative therapy
Yes 144 5 145 5 91 6 151 5 0.43
No 2770 95 2550 95 1403 94 2771 95
VLV: Very Low Volume (1–5 resections/year) LV: Low Volume (6–10 resections/year), MV: Medium Volume (11–20 resections/year), HV: High
Volume (P21 resections/year), SES: Socio Economic Status, SCC: squamous cell carcinoma, preoperative/postoperative therapy: chemotherapy
with/without radiotherapy.
a T4N1-3M0 and T1-4N3M0 gastric cancers were assigned stage IV in the 6th edition TNM-classiﬁcation
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high-volume hospitals increased from 7% to 64%, while
the number of gastrectomies performed in high-volume
hospitals decreased from 8% to 5%.
In 2009, 44 of the 92 hospitals (48%) in the Nether-
lands performed oesophagectomies, and 91 of the 92
hospitals performed gastrectomies.
3.3. Resection rates, mortality, survival and lymph node
yields over the years
Resection rates slightly decreased for oesophageal
cancer (from 1989 to 2009: 31–29%, P < 0.01), and
strongly decreased for gastric cancer (56–37%,
P < 0.01). Adjusted 6-month mortality after oesophag-
ectomy decreased from 14.8% in 1989 to 7.1% in 2009
(P < 0.001), while adjusted 6-month mortality after gas-
trectomy decreased to a lesser extent: from 15.2% in
1989 to 9.9% in 2009 (P < 0.001) (Fig. 3a). Adjusted 3-
year conditional survival signiﬁcantly increased after
oesophagectomy: from 41.0% in 1989 to 52.2% in 2009
(P < 0.001). Adjusted 3-year conditional survival aftergastrectomy increased to a lesser extent: from 55.0% in
1989 to 58.4% in 2009 (P < 0.01) (Fig. 3b). The improve-
ment in 6-month mortality and 3-year survival over time
was signiﬁcantly stronger after oesophagectomy, when
compared to gastrectomy (both P < 0.01).
Mean lymph node yield after oesophagectomy
increased from 10.1 in 1999 to 16.2 in 2009
(P < 0.001), and mean lymph node yield after gastrec-
tomy increased from 8.1 in 1999 to 12.4 in 2009
(P < 0.001).
3.4. Volume–outcome relations
Results from the multivariable analyses on volume–
outcome relations are shown in Table 3. After oeso-
phagectomy, medium and high volume hospitals were
associated with lower six-month mortality and longer
three-year conditional survival when compared to
very-low volume hospitals (Fig. 4). After gastrectomy,
neither six-month mortality or three-year conditional
survival were associated with hospital volume category
(Fig. 5). High hospital volume was associated with high
Table 2
Patient characteristics for all surgically treated patients with non-metastatic invasive gastric cancer in the Netherlands between 1989 and 2009
(N = 14,221).
VLV (1-5) LV (6-10) MV (11-20) HV (P21) P
N % N % N % N %
Total 3411 100 6099 100 4356 100 355 100
Sex
Male 1987 58 3707 61 2646 61 224 63 0.045
Female 1424 42 2392 39 1710 39 131 37
Age category
<60 689 20 1270 21 837 19 53 15 0.016
60–75 1606 47 2917 48 2074 48 165 46
>75 1116 33 1912 31 1445 33 137 39
SES
Low 378 11 783 13 560 13 53 15 <0.001
Medium 2665 78 4846 79 3559 82 294 83
High 118 3 230 4 106 2 8 2
Unknown 250 7 240 4 131 3 0 0
Morphology
Adenocarcinoma 3336 98 5985 98 4287 98 352 99 0.11
Other 75 2 114 2 69 2 3 1
TNM stage
I 1299 38 2279 37 1687 39 147 41 0.014
II 898 26 1675 27 1187 27 78 22
III 936 27 1718 28 1204 28 111 31
IVa 181 5 248 4 154 4 11 3
Unknown 97 3 179 3 124 3 8 2
Preoperative therapy
Yes 167 5 303 5 138 3 8 2 <0.001
No 3244 95 5796 95 4218 97 347 98
Postoperative therapy
Yes 139 4 236 4 122 3 12 3 0.009
No 3272 96 5863 96 4234 97 343 97
VLV: Very Low Volume (1–5 resections/year) LV: Low Volume (6–10 resections/year), MV: Medium Volume (11–20 resections/year), HV: High
Volume (P21 resections/year), SES: Socio Economic Status, preoperative/postoperative therapy: chemotherapy with/without radiotherapy.
a T4N1-3M0 and T1-4N3M0 gastric cancers were assigned stage IV in the 6th edition TNM-classiﬁcation
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gastrectomy.
When analysing hospital volume as a linear covariate,
volume–survival results remained the same. No changes
in the results were found when volume–outcome rela-
tions were analysed with surgery for cardia cancer coded
as gastrectomy (data not shown).
4. Discussion
Over the study period, the number of oesophagecto-
mies performed in high volume hospitals considerably
increased, while in 2009 most gastrectomies were per-
formed in low volume hospitals. Both 6-month mortal-
ity and 3-year survival improved after
oesophagectomy, but to a lesser extent after gastrec-
tomy. In the current dataset, a volume–survival relation
was revealed for oesophagectomy, but not for
gastrectomy.
Since Luft et al. published the ﬁrst study on volume–
outcome relations for surgery,16 many studies have
emerged investigating the eﬀect of hospital and surgeons
volume on short term and long term outcomes for avariety of diseases, including resections for oesophageal
and gastric cancers. Several large studies have shown an
association between high hospital volume and low post-
operative mortality both for oesophagectomy, 17–20 and
gastrectomy17,20–22, but other studies did not ﬁnd an
association.23–25 In a meta-analysis exploring volume–
outcome relations, high volume surgery was associated
with lower postoperative mortality after both oesophag-
ectomy and gastrectomy.9 A limited number of studies
investigate the relation between hospital volume and
long-term survival after oesophagectomy and gastrec-
tomy, with conﬂicting results.7,24,26,27
Over the past two decades, the number of oesophagec-
tomies in the Netherlands has increased, corresponding
with an increasing incidence of oesophageal cancer.42
The decreasing incidence of gastric cancer explains the
low number of gastrectomies currently performed in
the Netherlands.28 Furthermore, the resection rate for
gastric cancer dropped signiﬁcantly, most likely the
result of improved preoperative staging. Combined with
the almost complete disappearance of surgery for reﬂux
disease and ulcers, surgeons are decreasingly exposed
to gastrectomies. This might partly be compensated by
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Fig. 3. (a) Six-month mortality for oesophagectomy and gastrectomy,
adjusted for sex, age, socio-economic status, stage, morphology and
use of preoperative therapy (1989–2009). Oesophagectomy, hazard
ratio (HR) 0.96 for each year, P < 0.001. Gastrectomy, HR 0.98 for
each year, P < 0.001. Diﬀerence between oesophagectomy and gas-
trectomy: P = 0.003. (b) Three-year survival rate conditional on
surviving the ﬁrst 6 months for oesophagectomy and gastrectomy,
adjusted for sex, age, socio-economic status, stage, morphology and
use of preoperative and postoperative therapy (1989–2006). Oeso-
phagectomy, HR 0.97 for each year, P < 0.001. Gastrectomy, HR 0.99
for each year, P < 0.001. Diﬀerence between oesophagectomy and
gastrectomy: P < 0.001. (c) Median lymph node yield for oesophag-
ectomy and gastrectomy, adjusted for sex, age, stage and morphology
(1999–2009). Oesophagectomy: P < 0.001. Gastrectomy: P < 0.001.
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the surgical techniques used diﬀer signiﬁcantly.
In the current study, increasing hospital volume was
associated with lower mortality and increased long-term
survival after oesophagectomy, but not after gastrec-
tomy. This observation for gastrectomies might be
explained by the low number of high-volume gastrecto-
mies (2.5% of all gastrectomies in the current dataset),
and the low threshold for what was considered high-vol-
ume surgery. In other studies that did ﬁnd an associa-
tion between gastrectomy in high volumes and good
outcomes, the lower limit of high volume surgery varied
from 20/year up to 264/year.17,27
The current study covers an extensive period of two
decades of oesophago-gastric cancer surgery in the
Netherlands, and analyses a signiﬁcant population of
about 25,000 patients. Unlike many of the large vol-
ume–outcome studies, the current study uses a clinical
database with highly reliable data, providing complete
coverage of all diagnosed cancers in the Netherlands.
Furthermore, outcomes are case-mix adjusted, increas-
ing reliability of the results.29 The absence of comorbid-
ity in the current dataset was partly compensated by the
use of SES, which can be considered a proxy for
comorbidity.30
A potential bias when analysing outcomes over a long
period is that preoperative staging and (perioperative)care generally improve over time. For example,
endoscopic ultrasound, multislice high resolution
Table 3
Volume–outcome relations for oesophagectomy and gastrectomy (1989–2009). Mortality and survival were calculated with multivariable Cox
regression, nodal yield was calculated with generalised estimated equations.
Oesophagectomy Gastrectomy
Six-month mortality Three-year survivala LN yieldb Six-month mortality Three-year survivala LN yieldb
HR 95% CI HR 95% CI OR 95% CI HR 95% CI HR 95% CI OR 95% CI
Hospital volume
Very low (1–5/yr) 1.00 1.00 1.00 1.00 1.00 1.00
Low (6–10/yr) 0.90 0.78–1.03 1.01 0.94–1.10 1.00 0.91–1.09 0.95 0.84–1.07 0.99 0.91–1.07 1.02 0.96–1.08
Medium (11–20/yr) 0.78 0.62–0.97 0.90 0.81–0.99 1.10 1.00–1.22 0. 95 0.83–1.08 0.99 0.90–1.08 0.99 0.90–1.10
High (P21/yr) 0.48 0.38–0.61 0.77 0.70–0.85 1.50 1.25–1.80 1. 10 0.82–1.49 0.98 0.86–1.12 1.93 1.81–2.04
Year of diagnosis
1989–1993 1.00 1.00 1.00 1.00
1994–1997 0.91 0.78–1.07 0.92 0.83–1.01 0.96 0.86–1.07 0.98 0.90–1.05
1998–2001 0.82 0.68–0.98 0.88 0.79–0.97 1.00 0.89 0.79–1.01 0.94 0.87–1.02 1.00
2002–2005 0.69 0.55–0.86 0.69 0.63–0.75 1.18 1.10–1.25 0.74 0.65–0.85 0.88 0.81–0.96 1.08 1.02–1.16
2006–2009 0.67 0.52–0.85 0.75 0.63–0.75 1.42 1.27–1.60 0.70 0.60–0.81 0.78 0.72–0.86 1.42 1.32–1.52
Sex
Male 1.00 1.00 1.00 1.00 1.00
Female 0.75 0.66–0.86 0.83 0.78–0.89 1.04 1.00–1.08 0.79 0.73–0.85 0.91 0.85–0.97 1.10 1.05–1.14
Age category
<60 1.00 1.00 1.00 1.00 1.00 1.00
60–75 1.83 1.56–2.14 1.14 1.07–1.21 0.97 0.94–1.00 2.03 1.78–2.30 1.27 1.18–1.37 0.88 0.82–0.93
>75 3.10 2.54–3.79 1.41 1.25–1.59 0.87 0.82–0.92 3.94 3.47–4.49 1.57 1.44–1.71 0.75 0.69–0.81
SES
Low 1.00 1.00 1.00 1.00
Medium 0.76 0.64–0.90 1.05 0.96–1.16 0.92 0.81–1.04 1.01 0.92–1.12
High 0.54 0.38–0.78 1.00 0.85–1.17 0.70 0.55–0.91 1.00 0.84–1.20
Unknown 0.53 0.38–0.74 1.04 0.86–1.26 0.94 0.73–1.21 1.03 0.85–1.24
TNM stage
I 1.00 1.00 1.00 1.00 1.00 1.00
II 1.28 1.08–1.52 2.74 2.46–3.04 1.15 1.09–1.21 1.46 1.31–1.63 2.99 2.78–3.22 1.23 1.16–1.31
III 1.73 1.41–2.13 5.20 4.46–6.05 1.39 1.31–1.47 2.15 1.93–2.38 5.37 5.01–5.75 1.55 1.46–1.66
IV 3.85 2.55–5.81 9.76 7.43–12.81 1.93 1.70–2.20 3.50 3.00–4.08 8.45 7.43–9.61 2.23 2.05–2.42
Unknown 1.92 1.41–2.62 2.37 2.00–2.81 1.04 0.92–1.17 1.91 1.40–2.60 2.36 1.96–2.84 1.01 0.82–1.24
Morphology
Adenocarcinoma 1.00 1.00 1.00 1.00 1.00
SCC 1.26 1.11–1.43 1.09 0.98–1.21 1.05 0.99–1.11
Other 1.28 0.94–1.75 1.05 0.84–1.33 1.00 0.88–1.12 1.18 0.86–1.64 0.58 0.44–0.78 0.94 0.71–1.25
Preoperative therapy
No 1.00 1.00 1.00 1.00
Yes 0.32 0.23–0.43 0.84 0.76–0.93 0.27 0.17–0.43 1.05 0.84–1.31
Postoperative therapy
No 1.00 1.00 1.00
Yes 1.07 0.94–1.21 1.01 0.85–1.21
HR: hazard ratio, OR: odds ratio, SES: Socio Economic Status, SCC: squamous cell carcinoma, CI: conﬁdence interval, Bold: signiﬁcant
(P < 0.05).
a Conditional on surviving the ﬁrst six months.
b 1999–2009.
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were introduced resulting in improvement of staging.
Hospital volumes for oesophagectomy signiﬁcantly
change during the study period, with most high-volume
resections performed in the more recent years. Therefore,
high volume resections are intrinsically associated with
better outcomes. However, adjusting for year of diagno-
sis oﬀsets this eﬀect. Another potential weakness is the
unavailability of the surgery hospital for part of the
patients treated before 2005. Instead, the hospital of
diagnosis was used. However, this only happened in
the ﬁrst years of the study, when hospitals less frequently
referred patients to another hospital for surgery.A point of discussion might be that volumes are ana-
lysed on hospital level, rather than surgeon level.27,31,32
Quality of care, however, consists of more than an indi-
vidual surgeon’s performance. Perioperative care, anaes-
thesia, ICU staﬃng, experience of the nursery staﬀ and
collaboration between diﬀerent disciplines all contribute
to outcomes associated with the performed procedure.33
The role of the surgeon is only one, yet important, factor
contributing to outcome.
Initiatives to improve medical and especially surgical
care are legion. Randomised trials improve care by
selecting appropriate treatments for certain indica-
tions,3,34 and by educating surgeons participating in
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Fig. 5. Volume–outcome relations for gastrectomy. (a) Relation
between volume and 6-month survival, adjusted for year of diagnosis,
sex, age, socio-economic status, stage, morphology and preoperative
therapy use. *P < 0.05 compared to Very Low Volume. (b) Relation
between volume and 3-year survival, conditional on surviving the ﬁrst
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are treated outside trials, and especially improvements
in the process and structure of care on a nation-wide
level will bring beneﬁt to this group of patients. Many
studies have advocated the centralisation of low-volume,
high-risk operations, thereby improving nationwide
quality of care.11,27 Centralisation of oesophageal and
gastric cancer is currently performed in several Euro-
pean countries, whereas referral to high-volume centres
is also advocated in the United States by the Leapfrog
group.37 In Denmark, centralisation of gastric cancer
surgery from 37 to 5 hospitals leaded to a drop in post-
operative mortality from 8.4% to 2.1% over a period of
5 years.38
Unlike the Netherlands, which is a relatively small
country with good infrastructure, centralisation of care
in countries with large rural areas might lead to unrea-
sonable travel burdens and problems with continuity
of care after surgery. Therefore, others have advocated
implementing processes that are related to excellent out-
comes in low volume hospitals, but identiﬁcation of
these processes remains challenging.39Meanwhile, using hospital volume as the sole basis
for referral to improve outcomes is criticised.17
Although hospital volume can reliably identify groups
of hospitals with better results on average, individual
low volume hospitals can have excellent outcomes and
vice versa. In contrast to volume-based referral, out-
come based-referral avoids this problem, and has proven
its value for oesophagectomy in the Western part of the
Netherlands. In this area, a prospective audit was con-
ducted to identify hospitals with excellent performance
in oesophagectomy. During the ﬁve-year audit, a grad-
ual concentration towards centres with excellent perfor-
mance occurred, leading to a drop in postoperative
mortality (12–4%) and an improvement in survival.40
Combining centralisation with auditing substantially
adds to improvement of care.41 With auditing, providers
of care are monitored and their performance is bench-
marked against their peers. Auditing is performed on a
national level for oesophagogastric cancer in Den-
mark,38 Sweden and the United Kingdom. A nationwide
audit for both oesophageal and gastric cancer surgeries
has started in the Netherlands as of 2011 aiming for
1012 J.L. Dikken et al. / European Journal of Cancer 48 (2012) 1004–1013complete coverage of all oesophagectomies and
gastrectomies.
In conclusion, enforcing centralisation for oeso-
phagectomy in the Netherlands has resulted in a shift
in annual hospital volumes: most resections are cur-
rently performed in high volume centres. For gastrec-
tomy, no minimum number of resections was
required, and the majority of gastric cancer resections
were performed in low volume hospitals. However, as
of 2012 gastrectomies in the Netherlands will be cen-
tralised to a minimum of 10/year, and as of 2013 to
a minimum of 20/year. Oesophagectomy in high vol-
ume hospitals is associated with improved outcomes.
No such relation for gastric cancer could be estab-
lished in the current dataset, but only a minority of
patients was treated in high volume hospitals. Over
the past two decades, short-term mortality and long-
term survival after oesophagectomy decreased signiﬁ-
cantly, while outcomes after gastrectomy improved
to a lesser extent, indicating an urgent need for
improvement in quality of surgery and perioperative
care for gastric cancer in the Netherlands.Role of funding source
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